Posted by Michael Wonder on 20 Aug 2016
ICER releases draft evidence report on treatments for non-small-cell lung cancer
19 August 2016 - The ICER has released a draft evidence report assessing the comparative clinical effectiveness and value of treatments for non-small-cell lung cancer.
The report, as well as accompanying draft voting questions, will be open to public comment for four weeks.
This report evaluates the health outcomes and economic effects of certain tyrosine kinase inhibitors and programmed death 1 immunotherapy agents in the treatment of advanced non-small-cell lung cancer (NSCLC). The effects of both classes of agents are evaluated in epidermal growth factor receptor positive (EGFR+) NSCLC, and PD-1 agents are evaluated in EGFR- NSCLC.
